Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism.

The pharmacogenomics journal - 1 Oct 2007

Tiwari A K, Deshpande S N, Lerer B, Nimgaonkar V L, Thelma B K

Abstract excerpt

Tardive dyskinesia (TD) is an iatrogenic disorder observed in approximately 20-30% of schizophrenia patients on long-term treatment with typical antipsychotic drugs. CYP1A2 is involved in the metabolism of atypical antipsychotic drugs such as clozapine and olanzapine. It is not directly involved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Chronic Disease
Share to Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A2

Share to Dyskinesia, Drug-Induced

Share to Introns

Share to Risk Assessment

Share to Schizophrenia

Source

Identifiers

PMID: 16969362
DOI: 10.1038/sj.tpj.6500415

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16969362-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism.PMID 16969362Read ↗

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.Semantic proximity Read ↗

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.Semantic proximity Read ↗

Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetics of tardive dyskinesia: an updated review of the literature.Semantic proximity Read ↗

Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia.Semantic proximity Read ↗

Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population.Semantic proximity Read ↗

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.Semantic proximity Read ↗

Epidemiology and risk factors for (tardive) dyskinesia.Semantic proximity Read ↗

Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.Semantic proximity Read ↗

Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms.Semantic proximity Read ↗

Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical StudiesSemantic proximity Read ↗

Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.